Skip to Content
Merck
All Photos(1)

Key Documents

D6321

Sigma-Aldrich

Droxinostat

≥98% (HPLC)

Synonym(s):

4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C11H14ClNO3
CAS Number:
Molecular Weight:
243.69
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

color

white to off-white

solubility

DMSO: ≥20 mg/mL

storage temp.

2-8°C

SMILES string

Cc1cc(Cl)ccc1OCCCC(=O)NO

InChI

1S/C11H14ClNO3/c1-8-7-9(12)4-5-10(8)16-6-2-3-11(14)13-15/h4-5,7,15H,2-3,6H2,1H3,(H,13,14)

InChI key

JHSXDAWGLCZYSM-UHFFFAOYSA-N

Biochem/physiol Actions

Droxinostat is a selective inhibitor of HDAC3, HDAC6, and HDAC8.

Features and Benefits

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Pictograms

CorrosionExclamation mark

Signal Word

Danger

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral - Eye Dam. 1 - Skin Irrit. 2 - STOT SE 3

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Histone Deacetylase 3 Inhibition Overcomes
Azusa Tanimoto et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 23(12), 3139-3149 (2016-12-18)
Ying Huang et al.
Cellular & molecular biology letters, 23, 34-34 (2018-08-02)
Upregulation of histone acetylation plays a critical role in the dysregulation of transcription. It alters the structure of chromatin, which leads to the onset of cancer. Histone deacetylase inhibitors may therefore be a promising way to limit cancer progression. In
Gera Goverse et al.
Journal of immunology (Baltimore, Md. : 1950), 198(5), 2172-2181 (2017-01-20)
The gastrointestinal tract is continuously exposed to many environmental factors that influence intestinal epithelial cells and the underlying mucosal immune system. In this article, we demonstrate that dietary fiber and short chain fatty acids (SCFAs) induced the expression of the
Di Huang et al.
Nature immunology, 19(10), 1112-1125 (2018-09-19)
Activation-induced cell death (AICD) of T lymphocytes can be exploited by cancers to escape immunological destruction. We demonstrated that tumor-specific cytotoxic T lymphocytes (CTLs) and type 1 helper T (TH1) cells, rather than type 2 helper T cells and regulatory
Dominik Stammler et al.
Journal of immunology (Baltimore, Md. : 1950), 195(11), 5421-5431 (2015-11-01)
Histone deacetylase (HDAC) inhibitors (HDACi) are clinically approved anticancer drugs that have important immune-modulatory properties. We report the surprising finding that HDACi promote LPS-induced IL-1β processing and secretion in human and murine dendritic cells and murine macrophages. HDACi/LPS-induced IL-1β maturation

Articles

Epigenetic modifications are thought to occur through two key interconnected processes—DNA methylation and the covalent modification of histones.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service